BiomX Inc. (PHGE) recently announced the presentation of data from its Phase 1b/2a study for BX004 — a fixed multi-phage cocktail. BX004 is used for treating cystic fibrosis (CF) patients with chronic pulmonary infections caused by Pseudomonas aeruginosa (PsA). BiomX will present this study data at the North American Cystic Fibrosis Conference in Boston. PHGE Stock's Likely Trend Following the News Shares of PHGE rose 2.8% to $1.05 yesterday following the news. To date, BX004 has been under several trials. ...

GAITHERSBURG, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces the Company will present further data from BiomX's Phase 1b/2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections. The findings will be presented in two sessions at the North American Cystic Fibrosi ...

In a release issued under the same headline yesterday by BiomX (NYSE American: PHGE), the third and fourth paragraphs have been updated to include information regarding adjustment of outstanding units following the reverse stock split GAITHERSBURG, Md., Aug. 16, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline yesterday by BiomX (NYSE American: PHGE), the third and fourth paragraphs have been updated to include information regarding adjustment of outstanding units following the reverse s ...

Core Insights - BiomX anticipates reporting significant results in 2025 for two clinical assets, BX004 and BX211, from its phage therapy pipeline [1][2] - The company has successfully converted Series X Non-Voting Convertible Preferred Stock into common stock following a stockholder vote [1][6] - BiomX will host a conference call and webcast to discuss its financial results and corporate updates [1][12] Clinical Program Updates - BX004 is a fixed phage cocktail targeting chronic pulmonary infections in cystic fibrosis patients, with positive Phase 1b/2a trial results presented at major conferences [3][4] - In the BX004 arm, 14.3% of patients achieved negative sputum cultures for P. aeruginosa after 10 days, compared to 0% in the placebo group [4] - A Phase 2b trial for BX004 is expected to start, with results anticipated in Q3 2025 [5][14] - BX211 is a personalized phage treatment for diabetic foot osteomyelitis, currently in a Phase 2 trial with initial results expected in Q1 2025 [5][16] Business Update - BiomX's stockholders approved the conversion of Series X Preferred Stock into common stock, resulting in the addition of 109,152,000 shares to the outstanding share count [6] - The company received an Acceptance Letter from NYSE American, granting until November 23, 2025, to regain compliance with listing standards [7] Financial Results - As of June 30, 2024, BiomX reported a cash balance of $32.7 million, an increase from $30.7 million a year prior, primarily due to a $50 million financing [8] - Research and development expenses for Q2 2024 were $6.9 million, up from $3.8 million in Q2 2023, reflecting increased clinical trial preparations [9] - General and administrative expenses rose to $2.8 million in Q2 2024 from $2.3 million in Q2 2023, attributed to the merger's full consolidation [10] - The company reported a net income of $4.5 million for Q2 2024, a significant improvement from a net loss of $6.4 million in Q2 2023 [11]

GAITHERSBURG, Md., Aug. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it intends to effect a one-for-ten reverse split (the "Reverse Stock Split") of the Company's common stock (the "Common Stock"). The Common Stock will continue to trade on the NYSE American under the existing symbol "PHGE" and will begin trading on a spli ...

GAITHERSBURG, Md., July 29, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it received a notification (the "Acceptance Letter") from the NYSE American LLC (the "NYSE American"), dated July 23, 2024, stating that the NYSE American has accepted the Company's previously submitted plan to regain compliance with the NYSE American's l ...

"We are pleased the NYSE American has accepted our Plan to regain compliance," commented Jonathan Solomon, Chief Executive Officer of BiomX. "We intend to take all reasonable measures available to us and have already begun implementing our Plan, including by obtaining stockholders' approval for conversion of the Company's outstanding Series X Convertible Preferred Stock to Common Stock, as announced earlier this month." During the Plan Period, the Company will be subject to periodic review by the NYSE Ameri ...

BiomX's Series X Preferred Stock was issued upon BiomX's acquisition of Adaptive Phage Therapeutics, Inc. ("APT") and a concurrent $50 million financing (the "Financing"), which were consummated in March 2024. As a result of the stockholder vote approving the conversion of BiomX's Series X Preferred Stock, each share of Series X Preferred Stock issued in the APT acquisition and the private placement will be converted into 1,000 shares of BiomX common stock, subject to certain beneficial ownership limitation ...

Core Viewpoint - BiomX Inc. has received approval from its stockholders to convert its Series X Non-Voting Convertible Preferred Stock into common stock, which is expected to enhance its compliance with NYSE American listing requirements [1][2][5]. Group 1: Stockholder Vote and Conversion - The stockholder vote approved the conversion of BiomX's Series X Preferred Stock into common stock, allowing for the conversion of up to 256,887 shares into 256,887,000 shares of common stock [5]. - This conversion is a result of the financing associated with the acquisition of Adaptive Phage Therapeutics, Inc. and is expected to positively impact the company's balance sheet by classifying certain proceeds as stockholders' equity [2][5]. Group 2: Compliance with NYSE American - Following the stockholder vote, BiomX anticipates regaining compliance with NYSE American's requirement for listed companies to maintain stockholders' equity of at least $2 million [2]. - The company had previously been notified of non-compliance and submitted a plan to address this issue, awaiting acceptance from NYSE American [2]. Group 3: Company Overview and Future Prospects - BiomX is focused on developing novel phage therapies targeting pathogenic bacteria, with two advanced Phase 2 clinical candidates expected to have significant readouts in the coming year [6]. - The company utilizes its BOLT platform to customize phage compositions against proprietary bacterial targets, aiming to address chronic diseases with unmet medical needs [6].

GAITHERSBURG, Md. and NESS ZIONA, Israel, May 30, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it received written notification ("the Notice") from the NYSE American LLC ("NYSE American"), dated May 23, 2024, stating that the Company is no longer in compliance with continued listing standards, as set forth in Sections 1003(a) ...